UY39366A - Formas cristalinas de un inhibidor de la o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa - Google Patents
Formas cristalinas de un inhibidor de la o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasaInfo
- Publication number
- UY39366A UY39366A UY0001039366A UY39366A UY39366A UY 39366 A UY39366 A UY 39366A UY 0001039366 A UY0001039366 A UY 0001039366A UY 39366 A UY39366 A UY 39366A UY 39366 A UY39366 A UY 39366A
- Authority
- UY
- Uruguay
- Prior art keywords
- desoxi
- glucopyranosidase
- glucoprotein
- acetamido
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063060281P | 2020-08-03 | 2020-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39366A true UY39366A (es) | 2022-02-25 |
Family
ID=77640732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039366A UY39366A (es) | 2020-08-03 | 2021-08-03 | Formas cristalinas de un inhibidor de la o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230286972A1 (https=) |
| EP (1) | EP4188925A1 (https=) |
| JP (1) | JP7789056B2 (https=) |
| KR (1) | KR20230061395A (https=) |
| CN (1) | CN116917284A (https=) |
| AR (1) | AR123132A1 (https=) |
| AU (1) | AU2021322186A1 (https=) |
| BR (1) | BR112023002013A2 (https=) |
| CA (1) | CA3188250A1 (https=) |
| CL (1) | CL2023000327A1 (https=) |
| CO (1) | CO2023002543A2 (https=) |
| CR (1) | CR20230118A (https=) |
| IL (1) | IL300365A (https=) |
| MX (1) | MX2023001469A (https=) |
| PE (1) | PE20231168A1 (https=) |
| TW (1) | TW202220984A (https=) |
| UY (1) | UY39366A (https=) |
| WO (1) | WO2022031701A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2602139B (en) * | 2020-12-18 | 2024-07-24 | Nexeon Ltd | Electroactive materials for metal-ion batteries |
| WO2025184490A1 (en) | 2024-03-01 | 2025-09-04 | Biogen Ma Inc. | N-[4-fluor-5-[[(2s, 4 r)-4-[(6-methoxy-4-pyrimidinyl)oxy]- 2-methyl-1-pyrrolidinyl] methyl ]-2-thiazolyl]acetamid for use in the treatment of alzheimer disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2780014A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5989805B2 (ja) | 2012-02-10 | 2016-09-07 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | メチル基変更酵素の調節物質、組成物及びその使用 |
| MA38341B1 (fr) | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| EP3555087A1 (en) | 2016-12-16 | 2019-10-23 | Janssen Pharmaceutica NV | Monocyclic oga inhibitor compounds |
| TWI654978B (zh) | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5－甲基－1,2,4－二唑－3－基化合物 |
| WO2018154133A1 (en) | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
| US12180205B2 (en) * | 2018-09-19 | 2024-12-31 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
-
2021
- 2021-08-03 WO PCT/US2021/044341 patent/WO2022031701A1/en not_active Ceased
- 2021-08-03 PE PE2023000189A patent/PE20231168A1/es unknown
- 2021-08-03 TW TW110128540A patent/TW202220984A/zh unknown
- 2021-08-03 KR KR1020237007569A patent/KR20230061395A/ko active Pending
- 2021-08-03 CN CN202180066901.9A patent/CN116917284A/zh active Pending
- 2021-08-03 IL IL300365A patent/IL300365A/en unknown
- 2021-08-03 JP JP2023507579A patent/JP7789056B2/ja active Active
- 2021-08-03 BR BR112023002013A patent/BR112023002013A2/pt not_active Application Discontinuation
- 2021-08-03 AU AU2021322186A patent/AU2021322186A1/en active Pending
- 2021-08-03 EP EP21766024.0A patent/EP4188925A1/en active Pending
- 2021-08-03 AR ARP210102157A patent/AR123132A1/es unknown
- 2021-08-03 UY UY0001039366A patent/UY39366A/es unknown
- 2021-08-03 MX MX2023001469A patent/MX2023001469A/es unknown
- 2021-08-03 US US18/019,270 patent/US20230286972A1/en active Pending
- 2021-08-03 CA CA3188250A patent/CA3188250A1/en active Pending
- 2021-08-03 CR CR20230118A patent/CR20230118A/es unknown
-
2023
- 2023-02-01 CL CL2023000327A patent/CL2023000327A1/es unknown
- 2023-03-01 CO CONC2023/0002543A patent/CO2023002543A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202220984A (zh) | 2022-06-01 |
| CN116917284A (zh) | 2023-10-20 |
| PE20231168A1 (es) | 2023-07-26 |
| US20230286972A1 (en) | 2023-09-14 |
| AU2021322186A1 (en) | 2023-04-06 |
| BR112023002013A2 (pt) | 2023-05-02 |
| MX2023001469A (es) | 2023-06-16 |
| EP4188925A1 (en) | 2023-06-07 |
| CR20230118A (es) | 2023-06-02 |
| CA3188250A1 (en) | 2022-02-10 |
| CO2023002543A2 (es) | 2023-06-09 |
| JP7789056B2 (ja) | 2025-12-19 |
| CL2023000327A1 (es) | 2023-10-06 |
| JP2023536911A (ja) | 2023-08-30 |
| IL300365A (en) | 2023-04-01 |
| WO2022031701A1 (en) | 2022-02-10 |
| AR123132A1 (es) | 2022-11-02 |
| KR20230061395A (ko) | 2023-05-08 |
| WO2022031701A9 (en) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2023000252A (es) | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 | |
| CO2022017700A2 (es) | Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo | |
| MX2021004191A (es) | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. | |
| CO2022017072A2 (es) | Imidazopiridazinas como moduladores de il-17 | |
| ECSP22019360A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos | |
| CO2019007711A2 (es) | N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
| CO2023002543A2 (es) | Formas cristalinas de un inhibidor de la o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
| DK1689721T3 (da) | Aminopyrazolderivater som GSK-3-ihibitorer | |
| UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
| BR112023001861A2 (pt) | Composições e métodos para tratamento de doenças e distúrbios | |
| AR043444A1 (es) | Profarmacos de diaril-2- 5h -furanonas que liberan oxido nitrico como inhibidores de la ciclooxigenasa-2 | |
| BR112022007488A2 (pt) | Forma cristalina de base livre de um receptor c5a de componente do complemento | |
| SA523451700B1 (ar) | (pi3k) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز لعلاج السرطان | |
| MX2018014298A (es) | Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida. | |
| CO2024003723A2 (es) | Compuestos de imidazopiridazina inhibidores de il-17 | |
| RU2008107733A (ru) | Ингибиторы gsk-3 | |
| MX2021006724A (es) | Compuestos de halo-alilamina y uso de los mismos. | |
| MX2022013650A (es) | Imidazopirimidinas como moduladores de il-17. | |
| CO2023010010A2 (es) | Composición farmacéutica que comprende un derivado de difenilpirazina | |
| EA202190308A1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера | |
| CL2025001501A1 (es) | Inhibidores de proteasas para tratar o prevenir la infección por coronavirus. | |
| MX2023012521A (es) | Formas en estado solido de (s)-n-(3-(2-((r)-1-hidroxipropano-2-il) amino)-6-morfolinopiridin-4-il)-4-metilfenil)-3-(2,2,2-trifluoroe til)pirrolidin-1-carboxamida y sales de las mismas. | |
| MX2019008118A (es) | Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino- 2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo]. | |
| CO2025001506A2 (es) | Formas sólidas de un derivado de triazina como modulador cbl-b | |
| AR131692A1 (es) | Formas cristalinas o sales de un compuesto deuterado |